Literature DB >> 29386731

Severe ovarian hyperstimulation syndrome: Can we eliminate it through a multipronged approach?

Nikita Naredi1, S K Singh2, Prasad Lele3, N Nagraj4.   

Abstract

BACKGROUND: Prevention of severe Ovarian Hyperstimulation Syndrome (OHSS), a potentially fatal complication of controlled ovarian hyperstimulation has been the aim of all fertility experts. Various pharmacologic and non-pharmacologic interventions have been instituted but the results have been conflicting. These preventive strategies were administered in isolation or as a combination of few aiming to eliminate this iatrogenic sequel. This study aimed to eliminate severe OHSS by multipronged approach incorporating almost all preventive modalities available in patients at high risk for this dreadful complication.
METHODS: It was a prospective observational study wherein 112 high risk patients planned for IVF were studied. The multipronged approach was in the form administering calcium gluconate infusion, cabergoline, albumin infusion, GnRH antagonist in luteal phase in addition to elective cryopreservation of embryos. The primary outcome measure was incidence of severe OHSS in the study group and the rate of hospitalisation. The secondary outcome measure was the number of days required for complete recovery and resolution of signs and symptoms.
RESULTS: Out of the 112 high risk patients only one patient (1/112; 0.9%) developed severe OHSS with an overall incidence of 0.095% of severe OHSS in all the cycles. There was no biochemical or haematological derangement in any of the high risk patients.
CONCLUSION: Although this is the first study evaluating the multipronged approach in preventing the dreaded complication of severe OHSS, it does add to the knowledge that targeting the various pathophysiological pathways at different time frames will bring about prevention of OHSS but further randomised studies may reveal superiority of one intervention over the other.

Entities:  

Keywords:  Cabergoline; Calcium gluconate; Multipronged approach; Ovarian hyperstimulation syndrome; Vascular endothelial growth factor

Year:  2017        PMID: 29386731      PMCID: PMC5771764          DOI: 10.1016/j.mjafi.2017.04.006

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  37 in total

1.  Human embryos with unevenly sized blastomeres have lower pregnancy and implantation rates: indications for aneuploidy and multinucleation.

Authors:  T Hardarson; C Hanson; A Sjögren; K Lundin
Journal:  Hum Reprod       Date:  2001-02       Impact factor: 6.918

Review 2.  Current status of human oocyte and embryo cryopreservation.

Authors:  Leyre Herrero; Mónica Martínez; Juan A Garcia-Velasco
Journal:  Curr Opin Obstet Gynecol       Date:  2011-08       Impact factor: 1.927

3.  Patient satisfaction with inpatient versus outpatient reconstruction of the anterior cruciate ligament: a randomized clinical trial.

Authors:  Steven A Krywulak; Nicholas G H Mohtadi; Margaret L Russell; Treny M Sasyniuk
Journal:  Can J Surg       Date:  2005-06       Impact factor: 2.089

Review 4.  Physiology and pathology of ovarian hyperstimulation syndrome.

Authors:  Raúl Gómez; Sergio R Soares; Cristiano Busso; Juan A Garcia-Velasco; Carlos Simón; Antonio Pellicer
Journal:  Semin Reprod Med       Date:  2010-11-16       Impact factor: 1.303

5.  Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.

Authors:  Raul Gomez; Miguel Gonzalez-Izquierdo; Ralf C Zimmermann; Edurne Novella-Maestre; Isabel Alonso-Muriel; Jose Sanchez-Criado; Jose Remohi; Carlos Simon; Antonio Pellicer
Journal:  Endocrinology       Date:  2006-08-10       Impact factor: 4.736

6.  Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology.

Authors:  A La Marca; S Giulini; A Tirelli; E Bertucci; T Marsella; S Xella; A Volpe
Journal:  Hum Reprod       Date:  2006-10-27       Impact factor: 6.918

7.  Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study.

Authors:  Claudio Alvarez; Isabel Alonso-Muriel; Gabriela García; Juana Crespo; José Bellver; Carlos Simón; Antonio Pellicer
Journal:  Hum Reprod       Date:  2007-10-04       Impact factor: 6.918

8.  Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome.

Authors:  N McClure; D L Healy; P A Rogers; J Sullivan; L Beaton; R V Haning; D T Connolly; D M Robertson
Journal:  Lancet       Date:  1994-07-23       Impact factor: 79.321

Review 9.  Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS).

Authors:  Annick Delvigne; Serge Rozenberg
Journal:  Hum Reprod Update       Date:  2003 Jan-Feb       Impact factor: 15.610

10.  New algorithm for OHSS prevention.

Authors:  Evangelos G Papanikolaou; Peter Humaidan; Nikos Polyzos; Sofia Kalantaridou; Sahar Kol; Claudio Benadiva; Herman Tournaye; Basil Tarlatzis
Journal:  Reprod Biol Endocrinol       Date:  2011-11-03       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.